Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Toripalimab Combined With Chemotherapy in Rare Mutations Stage IIB-IIIB NSCLC

NCT05800340 is registered in ClinicalTrials.gov with Guangdong Provincial People's Hospital as lead sponsor.

NCT NCT05800340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Toripalimab Combined With Chemotherapy in Rare Mutations Stage IIB-IIIB NSCLC
Lead sponsor
Guangdong Provincial People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 4, 2023
Completion date
December 31, 2026
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, erb-b2 receptor tyrosine kinase exon 20 mutation, met amplification, met exon 14 skipping mutation, non-small cell lung cancer, ret driver mutation